Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ebastine→

Ebastine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
90729-43-4
Molecular formula
C32H39NO2
Molecular weight
469.7 g/mol
Drug class
Second-generation, selective peripheral H1-histamine receptor antagonist
Mechanism of action
Ebastine and its active metabolite produce rapid and prolonged, highly selective antagonism of peripheral histamine H1 receptors. They have low penetration of the blood–brain barrier and little anticholinergic activity, consistent with relatively low sedation.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
  • Urticaria and other histamine-mediated allergic symptoms, according to the specific product authorisation

Sources: Dutch Medicines Evaluation Board (CBG) SmPC — Ebastine · Cyprus Ministry of Health SmPC — Ebastel (ebastine) · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Second-generation, selective peripheral H1-histamine receptor antagonist

Mechanism of action

Ebastine and its active metabolite produce rapid and prolonged, highly selective antagonism of peripheral histamine H1 receptors. They have low penetration of the blood–brain barrier and little anticholinergic activity, consistent with relatively low sedation.

General use cases

  • Symptomatic treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
  • Urticaria and other histamine-mediated allergic symptoms, according to the specific product authorisation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Ebastine Environmental Risk Assessment (ERA) (the Ebastine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.